BDRX — Biodexa Pharmaceuticals Plc
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1643918 ·
United Kingdom
Last close
$2.14
Market Cap
$2.20M
52W High
$357.60
52W Low
$2.14
ADV30
356,390
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | 12,721,000 | 3,230,000 | 3,108,000 |
| Dec 2025 | — | — | — | — | 18,179,000 | 8,534,000 | 6,774,000 |
| Jun 2025 | — | — | — | — | 14,824,000 | 4,036,000 | 3,388,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-157,600,000
Inventory
—
Receivables
$3,460,000
ST Investments
—
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
1
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -8,645,000 | -6,384,000 | 18,179,000 | 6,774,000 | 11,405,000 | -5,591,000 |
| Dec 2024 | 0 | -9,199,000 | -5,729,000 | 14,780,000 | 6,458,000 | 8,322,000 | -12,261,000 |
| Dec 2023 | 381,000 | -8,014,000 | -7,079,000 | 10,500,000 | 5,860,000 | 4,678,000 | -6,826,000 |
| Dec 2022 | 699,000 | -8,932,000 | -7,656,000 | 5,530,000 | 2,362,656 | 3,162,344 | -7,048,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.00
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| REVB | REVELATION BIOSCIENCES, INC. | $2.21M | $3.88 | — |
| CVSI | CV Sciences, Inc. | $2.17M | $0.01 | — |
| DCOY | Decoy Therapeutics Inc. | $2.26M | $0.95 | — |
| RDHL | RedHill Biopharma Ltd. | $2.13M | $0.35 | — |
| PRFX | PRF Technologies Ltd. | $2.31M | $0.66 | — |
News headlines (Yahoo Finance, 1h cache)
Biodexa provides R&D Update
2026-11-09 13:30 · Yahoo
Biodexa Reaches 100-Patient Enrollment Milestone in Phase 3 Serenta Trial as Key Analysis Timeline Accelerates
2026-10-13 13:51 · Yahoo
Biodexa announces another Serenta milestone with 100 patients enrolled in its registrational Phase 3 trial in FAP
2026-10-13 12:30 · Yahoo
BDRX: Enrollment in Phase 3 SERENTA Trial Reaches 92 Patients
2026-09-22 11:26 · Yahoo
Interim results for the six months ended June 30, 2026
2026-09-11 20:30 · Yahoo
Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP
2026-08-19 12:30 · Yahoo
European Equities Traded in the US as American Depositary Receipts Track Higher in Wednesday Trading
2026-09-02 15:13 · Yahoo
European Equities Traded in the US as American Depositary Receipts Rise Marginally in Friday Trading
2026-11-13 16:17 · Yahoo
European Equities Traded in the US as American Depositary Receipts Advance Sharply in Wednesday Trading
2026-11-04 16:13 · Yahoo
European Equities Traded in the US as American Depositary Receipts Edge Lower in Wednesday Trading
2026-10-14 15:10 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.